Fig. 3: Stabilizing effects of Rpk9 mutations in variant RBD components and NPs. | npj Vaccines

Fig. 3: Stabilizing effects of Rpk9 mutations in variant RBD components and NPs.

From: Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens

Fig. 3

A Representative melting curves of RBD-I53-50A trimers with and without Rpk9 mutations. Melting temperatures (Tm) are indicated. B Hydrogen/deuterium exchange mass spectrometry of selected RBD peptides. Left, RBD structure with observed peptides numbered and regions where the VOC-related and Rpk9 mutations reside represented in blue and pink, respectively. C SEC chromatograms of RBD-NPs in three different buffers. MS: 50 mM Tris pH 7.4, 185 mM NaCl, 100 mM arginine-HCl, 4.5% v/v glycerol, 0.75% w/v CHAPS; TAG: 50 mM Tris pH 8, 150 mM NaCl, 100 mM arginine-HCl, 5% v/v glycerol; TBS: 50 mM Tris pH 8, 150 mM NaCl. Major peak at ~10.5 mL represents assembled NP and minor peak ~17 mL represents excess VOC-RBD-I53-50A. Black triangle on the x axis represents the Wu-1-RBD-NP peak in MS. D Representative aggregation profiles of purified RBD-NPs, with temperature (Tagg) indicated.

Back to article page